Boehringer trims Connecticut workforce as sales suffer

Struggling with falling sales, Boehringer Ingelheim is trimming its workforce in Connecticut, which accounts for about 2,700 staffers altogether. 

A company spokesperson tells FierceBiotech that less than 5% of its staff at the Ridgefield site is affected by the move, or 2% of the total, but the company is looking to find new positions for some of the people involved in the cutback. 

"Boehringer Ingelheim is in the process of rebalancing its workforce in the U.S. to put the company in the best position for future growth," the company says in a statement. 

The 294-acre Ridgefield campus is the site of one of three major R&D centers for Boehringer and serves as its U.S. headquarters. Boehringer announced plans for a $65 million facility to support R&D and production back in 2011.

Just weeks ago the company reviewed a possible move to sell its $2.3 billion generics unit and a facility in Columbus, OH. Last fall Boehringer also said it would trim hundreds of jobs in Germany to account for a 5% drop in sales and a reduced forecast for the second half of the year.

Suggested Articles

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets. 

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.